ACADIA Pharmaceuticals (NASDAQ:ACAD) Announces Quarterly Earnings Results

ACADIA Pharmaceuticals (NASDAQ:ACAD) posted its earnings results on Wednesday. The biopharmaceutical company reported $0.31 earnings per share for the quarter, topping analysts’ consensus estimates of $0.20 by $0.11, FiscalAI reports. ACADIA Pharmaceuticals had a return on equity of 9.03% and a net margin of 33.42%. The firm had revenue of $342.30 million for the quarter, compared to the consensus estimate of $332.58 million. During the same quarter in the prior year, the business earned $0.42 EPS. The business’s revenue for the quarter was up 22.8% on a year-over-year basis.

Here are the key takeaways from ACADIA Pharmaceuticals’ conference call:

• ACADIA reported $342 million in Q3 revenue, up 22% year over year on an adjusted basis. DAYBUE sales reached a record $140 million, up 39%, while NUPLAZID generated $202 million, up 12%; growth for both brands was largely volume-driven.
• ACADIA raised its 2026 DAYBUE sales guidance to $505 million–$520 million, citing STIX momentum, with more than half of U.S. patients using the formulation by quarter-end. The company also highlighted its Germany launch and a newly allowed U.S. patent expected to protect both formulations through March 2041, while reiterating its $700 million sales ambition for 2028.
• NUPLAZID guidance was narrowed to $760 million–$775 million, with management citing the time needed for its expanded sales force to build prescribing relationships. ACADIA maintained its ambition of approximately $1 billion in NUPLAZID sales by the end of 2028.
• The phase II RADIANT trial of remlifanserin in Alzheimer’s disease psychosis narrowly missed statistical significance on its primary endpoint (p=0.0603), although the 60 mg dose showed activity across four efficacy scales and a nominally significant result on a key secondary endpoint. ACADIA plans to advance the 60 mg dose and adjust trial conduct and statistical methods for phase III; the primary endpoint remains unchanged.
• ACADIA expects phase II results for remlifanserin in Lewy body dementia psychosis and for ACP-211 in major depressive disorder in the second half of 2027, extending the timeline for pipeline updates. The company ended the quarter with $976 million in cash.

ACADIA Pharmaceuticals Price Performance

ACADIA Pharmaceuticals stock traded up $0.90 during mid-day trading on Wednesday, reaching $21.47. The stock had a trading volume of 4,719,887 shares, compared to its average volume of 1,533,597. The company has a market capitalization of $3.70 billion, a price-to-earnings ratio of 9.67 and a beta of 0.87. The company has a 50-day moving average price of $23.20 and a two-hundred day moving average price of $23.64. ACADIA Pharmaceuticals has a one year low of $18.39 and a one year high of $30.96.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on ACAD. UBS Group cut ACADIA Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $49.00 to $23.00 in a research note on Tuesday, October 13th. TD Cowen reissued a “buy” rating on shares of ACADIA Pharmaceuticals in a research report on Thursday, September 24th. HC Wainwright dropped their price objective on shares of ACADIA Pharmaceuticals from $37.00 to $33.00 and set a “buy” rating on the stock in a research note on Friday, September 25th. Citigroup reaffirmed a “buy” rating and set a $33.00 target price (down from $40.00) on shares of ACADIA Pharmaceuticals in a research note on Friday, September 25th. Finally, William Blair set a $33.00 target price on shares of ACADIA Pharmaceuticals in a research note on Monday, September 28th. Thirteen analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat.com, ACADIA Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $31.34.

Insider Buying and Selling

In other ACADIA Pharmaceuticals news, EVP Mark Schneyer sold 3,321 shares of the firm’s stock in a transaction dated Friday, October 30th. The shares were sold at an average price of $20.88, for a total transaction of $69,342.48. Following the completion of the sale, the executive vice president directly owned 71,322 shares in the company, valued at approximately $1,489,203.36. This trade represents a 4.45% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 26.20% of the company’s stock.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing medicines for central nervous system and neuropsychiatric disorders. The company’s research programs target conditions with significant unmet medical needs, including neurological and rare neurodevelopmental diseases.

ACADIA’s commercial products include NUPLAZID (pimavanserin), an atypical antipsychotic approved in the United States to treat hallucinations and delusions associated with Parkinson’s disease psychosis.